MedTrace Logo

Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma

NCT01503177 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-01-11

No results posted yet for this study

Summary

This phase I clinical trial investigates the side effects and the best dose of local (intrapleural measles virus therapy in treating patients with malignant pleural mesothelioma (MPM). The investigators anticipate that the intrapleural of the vaccine strain measles virus will enable the virus to specifically infect and kill cancer cells and spare, without damaging normal cells. Furthermore, the investigators expect the measles virus to trigger an anti-tumor immune response which will result in additional destruction of the tumor by immune cells

Conditions

  • Recurrent Malignant Mesothelioma
  • Stage IA Malignant Mesothelioma
  • Stage IB Malignant Mesothelioma
  • Stage II Malignant Mesothelioma
  • Stage III Malignant Mesothelioma
  • Stage IV Malignant Mesothelioma

Interventions

BIOLOGICAL

oncolytic measles virus encoding thyroidal sodium iodide symporter

Given intrapleurally

OTHER

laboratory biomarker analysis

Correlative studies

PROCEDURE

single photon emission computed tomography

Correlative studies

PROCEDURE

computed tomography

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Tobias Peikert · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2019-04-11
Completion
2019-04-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01503177 on ClinicalTrials.gov